<DOC>
	<DOCNO>NCT00123604</DOCNO>
	<brief_summary>The purpose study compare vascular effect two commonly use blood pressure medication , carvedilol metoprolol hypertensive patient type 2 diabetes .</brief_summary>
	<brief_title>Vascular Effects Carvedilol Versus Metoprolol Hypertensive Patients With Type 2 Diabetes</brief_title>
	<detailed_description>Carvedilol metoprolol two commonly use blood pressure medication show effective control hypertension . Although drug class , preliminary data show medication may different vascular effect . This study assess medication well improve artery health independent blood pressure lower effect . Artery health assess non-invasively ultrasound . Certain marker atherosclerosis find blood also measure .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<criteria>Age 3080 year old Documented history type 2 diabetes Stable angiotensin convert enzyme/angiotensin receptor blocker ( ACE/ARB ) regimen 30 day throughout study period Stable antidiabetic regimen throughout study period Body mass index ( BMI ) 2245 kg/m2 HbA1c 69 % patient antidiabetic treatment regimen HbA1c 68 % patient control diet alone Screening blood pressure ( BP ) &gt; 130/80 ( average 3 sit measurement ) , current medication Uncontrollable symptomatic arrhythmia Unstable angina Sick sinus syndrome second third degree heart block Decompensated heart failure Myocardial infarction ( MI ) stroke within 3 month screen Bradycardia Chronic obstructive pulmonary disease ( COPD ) require inhaled oral bronchodilator corticosteroids Bronchial asthma relate bronchospastic condition New onset/diagnosed type 2 diabetes ( &lt; 3 month ) Clinically significant renal liver disease ( creatinine &gt; 2.5 mg/dL ) Endocrine disorder Use anorectic diet drug inconsistent recommendation type 2 diabetic Use betablockers within 3 month screen Use corticosteroid Systemic disease , include cancer , reduce life expectancy ( &lt; 12 month ) Psychological illness/condition interfere comprehension study requirement Use investigational drug within 30 day entry study</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>beta-blockers</keyword>
	<keyword>endothelial function</keyword>
</DOC>